Similar dose-dependent increases in tumor lysis were observed in SW1353 chondrosarcoma cells, with 70% tumor lysis in CSPG4 CAR T cell treated cells at an E:T ratio of 1:1 versus <5% tumor lysis in the CD19 CAR T cell treated group (Figure 4). This evidence concerns the gene CD19 and chondrosarcoma.